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Article points
1. Glycated haemoglobin 
(HbA1c) is an important guide 
to glycaemic control and 
influences treatment decisions. 
Two consecutive HbA1c levels 
greater than 48 mmol/mol 
(6.5%) is associated with a 
linear increase in the incidence 
of diabetes complications, 
especially if the HbA1c 
continues to increase.
2. A number of factors can affect 
HbA1c, for example, conditions 
that affect red blood cell 
survival and non-enzymatic 
glycosylation of haemoglobin. 
Other factors include genetics, 
female gender, sex hormones, 
visceral fat distribution and 
the HbA1c assay method.
3. It is important to consider 
HbA1c results in the context 
of the individual when 
making diagnostic and 
therapeutic decisions.
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Glycated haemoglobin (HbA1c) reflects the average blood glucose level in the three 
months preceding the test. Changes in consecutive HbA1c tests indicate deteriorating, 
or improved, glycaemic control.  HbA1c is considered to be the “gold standard” measure 
of blood glucose control and is often used as the basis for prescribing choices and 
other care decisions. A number of factors can affect the accuracy of the HbA1c result, 
for example, the life span of red blood cells, assay methods and clinicians’ awareness 
of possible interfering factors. The aim of this article is to outline how HbA1c is used 
as a diagnostic test, how it is used to monitor glycaemic control and how it can guide 
management decisions. It is also important to emphasise the importance of considering 
HbA1c in the context of the individual rather than as an isolated number. 
G lycated haemoglobin (HbA1c) is an important guide to glycaemic control and inf luences treatment decisions. 
Several epidemiological studies, including the 
DCCT (Diabetes Control and Complications 
Trial; 1993) and the UKPDS (United Kingdom 
Prospective Diabetes Study; Turner et al, 1998) 
demonstrated that elevated HbA
1c
 is a strong 
predictor of diabetes-related morbidity. Two 
consecutive HbA
1c
 levels greater than 48 mmol/
mol (6.5%) is associated with a linear increase 
in the incidence of diabetes complications, 
especially if the HbA
1c
 values continue to 
increase (DCCT, 1993; Turner et al, 1998). 
Consequently, HbA
1c
 is now an accepted 
measure of long-term glycaemia, as well as a 
clinically relevant measure of glycaemic control. 
Although, there is an increasing body of 
evidence to suggest HbA
1c
 alone does not always 
accurately ref lect the individual’s metabolic 
status (Weber and Schnell, 2009). Recent 
research suggests glucose variability (peaks and 
nadirs lasting minutes to hours during the day) 
is a risk factor for microalbuminuria (Hsu et al, 
2012), adverse cardiovascular outcomes (Picconi 
et al, 2012) and all-cause mortality in type 2 
diabetes (Ma et al, 2011).
Glycaemia and diabetes management
HbA
1c
 was measured chromatographically 
in the DCCT and UKPDS. Chromographic 
methods detect several haemoglobin variants 
and non-HbA
1c
 glycohaemoglobins and tend 
to overestimate HbA
1c 
compared to modern 
assay methods (Larese, 2012). A considerable 
international effort has been undertaken in 
recent years to standardise existing HbA
1c
 
assays in current use and to standardise 
how glycated haemoglobin and estimated 
average blood glucose are reported (National 
Glycohemoglobin Standardisation Program, 
www.ngsp.org).
HbA
1c
 in people without diabetes usually 
ranges between 20 and 41 mmol/mol (4–5.9%; 
Diabetes.co.uk, 2013). HbA
1c
 consistently 
>53 mmol/mol (7%) in people with diabetes 
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represents inadequate glycaemic control and 
is associated with increased risk of long-term 
diabetes complications (Ray et al, 2009). The 
American Diabetes Association (ADA, 2011) 
and the World Health Organisation (WHO, 
2011) recommend aiming for an HbA
1c
 value 
<48 mmol/mol (6.5%).
NICE (2009) guidelines for type 2 
diabetes recommend aiming for HbA
1c
 levels 
<48 mmol/mol (6.5%) for people taking one 
blood glucose-lowering medicine (GLM) and 
<58 mmol/mol (7.5%) for those taking two or 
more GLMs. However, NICE acknowledged 
these levels may not be appropriate for 
all people with type 2 diabetes. Likewise, 
the Australian Diabetes Society (ADS, 
2009) suggested a general HbA
1c
 target of 
<53 mmol/mol (7%), but indicated some people 
should aim for <42 mmol/mol (6%) and some 
<64 mmol/mol (8%), depending on individual 
circumstances.
Significantly, HbA
1c
 <53 mmol/mol (7%) is 
associated with more frequent hypoglycaemia, 
which puts some people with diabetes, 
particularly older people, at increased 
risk of adverse events, including cognitive 
impairment, impaired decision-making, falls 
and myocardial infarction (The ACCORD 
Study Group, 2011). Thus, there is growing 
recognition that HbA
1c
 levels <53 mmol/mol 
(7%) may not be appropriate for everybody with 
diabetes and that management goals need to be 
individualised, especially in children and older 
people (ADS, 2009; NICE, 2009; Gale, 2010; 
Scottish Intercollegiate Guideline Network, 
2010). 
ADA (2011) have indicated that  HbA
1c
 values 
of 37–48 mmol/mol (5.7–6.4%) represent 
pre-diabetes, which is part of a continuum of 
diabetes risk and a marker of cardiovascular 
disease, and identifying pre-diabetes enables 
early treatment to be implemented to reduce the 
risk. Some authorities suggest repeating the test 
in asymptomatic people (d’Emden et al, 2012), 
which could mean diabetes is diagnosed earlier 
and treatment can be initiated sooner.  Likewise, 
the WHO (2011) cautioned that an HbA
1c
 <48 
mmol/mol (6.5%) does not exclude diabetes. In 
addition, it is important to consider factors that 
cause false high or low HbA
1c
 when interpreting 
results before making a definitive diagnosis.
HbA1c as a diagnostic tool
The WHO (2011), International Diabetes 
Federation (IDF; 2013) and the ADA (2011) 
recommend that HbA
1c
 is used as a diagnostic 
test for diabetes and cited values of HbA
1c
 
48 mmol/mol (6.5%) as the diagnostic 
cut-off point.  HbA
1c
 overcomes some of the 
methodological, procedural and practical 
problems associated with using blood glucose 
to make the diagnosis. These include the 
significant day-to-day variations in blood 
glucose levels, the fall in blood glucose 
concentration in blood samples, even when 
they are collected in f luoride-oxalate tubes, and 
inter-laboratory variations (d’Emden et al, 2012). 
In Australia, d’Emden et al (2012) have stated 
that HbA
1c
 has an important place in diagnosis 
when using the recommended diagnostic cut-off 
point, but suggested the test should be repeated 
in asymptomatic people with a diagnostic 
HbA
1c
 result to confirm the diagnosis. They 
further stated that HbA
1c
 should not be used 
as a general diabetes screening test and that 
initial screening should still be based on the 
Australian Type 2 Diabetes Risk Assessment 
Tool (AUSDRISK) score (Australian 
Government Department of Health and Ageing, 
2008).  The AUSDRISK is widely used in 
Australia to screen for diabetes; other countries 
have similar screening tools, such as the UK 
Diabetes Risk Score (Diabetes UK, 2013). In 
addition, d’Emden et al recommend that health 
professionals consider other factors that can 
affect the HbA
1c
 level when interpreting the 
result and making management decisions; see 
Box 1 and Table 1.
Page points
1. NICE recommend 
aiming for HbA1c levels 
<48 mmol/mol (6.5%) for 
people taking one blood 
glucose-lowering medicine 
(GLM) and <58 mmol/mol 
(7.5%) for those taking two or 
more GLMs. However, NICE 
acknowledged these levels 
may not be appropriate for all 
people with type 2 diabetes.
2. There is growing recognition 
that HbA1c levels <53 mmol/mol 
(7%) may not be appropriate for 
everybody with diabetes and 
that management goals need 
to be individualised, especially 
in children and older people.
3. HbA1c overcomes some of the 
methodological, procedural 
and practical problems 
associated with using blood 
glucose to make the diagnosis. 
These include the significant 
day-to-day variations in blood 
glucose levels, the fall in 
blood glucose concentration 
in blood samples and 
inter-laboratory variations.
Box 1. Main types of haemoglobinopathies
l Sickle cell anaemia.
l Sickle cell haemoglobin A disease.
l Sickle cell beta thalassaemia.
l Sickle cell haemoglobin D disease.
l Thalassaemia beta variants.
l Other rare genetic variants.
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HbA
1c
 is less reliable as a diagnostic tool 
in certain groups people, for example, those 
with cystic f ibrosis-related diabetes (Dyce and 
Wallymahmed, 2012); people on long-term 
corticosteroid medicines (Tidy, 2012); those 
with long-standing iron deficiency anaemia 
(Stranks and Doogue, 2012) and people with 
renal disease on haemodialysis (Vos et al, 2011). 
In addition, point-of-care HbA
1c
 test methods 
are useful to monitor glycaemic control but may 
not be accurate enough to diagnose diabetes 
(International Expert Committee, 2009).
Factors that affect HbA1c 
A number of factors can affect HbA
1c
, 
especially conditions that affect red blood 
cell survival and non-enzymatic glycosylation 
of haemoglobin (Herman, 2009; d’Emden 
et al, 2012). Herman (2009) suggested only 
approximately one third of the variance in 
HbA
1c
 is due to glycaemia. Other factors that 
affect HbA
1c
 include genetics, female gender, 
sex hormones, visceral fat distribution (Cohen 
et al, 2006) and the HbA
1c
 assay method. 
For example, immunoassay methods yield 
lower results than high performance liquid 
chromatography (HPLC; Schweitzer et al, 
2012). 
Formation of glycated haemoglobin
Glycation is a non-enzymatic, time-dependent 
chemical process during which glucose binds 
to the amino proteins in various tissues in 
the body (Little and Roberts, 2009). Glucose 
attaches to haemoglobin in the blood and 
several processes occur to form HbA
1c
. Several 
HbA peaks can be observed on chromographic 
assays: HbA
1a
, HbA
1b
 and HbA
1c
. HbA 
comprises 96–98% of the total haemoglobin 
and HbA
1c
 is the dominant component that 
Factors that can increase HbA1c Factors that can lower HbA1c
Asplenia Recent blood transfusion
Genetic heterozygous variants of haemoglobins S, 
C and E
Increased erythropoiesis secondary to haemolysis or 
blood loss
Large vitamin C doses with some assay methods* Acute and chronic blood loss
Long-standing iron deficiency Haemolytic anaemia
B12 deficiency Hereditary persistence of haemoglobin F
Medications, such as corticosteroids and 
antipsychotic agents
Genetic heterozygous variants of haemoglobins S, C 
and E*
Malaria End-stage kidney disease due to anaemia, 
malnutrition and haemodialysis
Rheumatoid arthritis Large vitamin doses of vitamin C and E
Hyperbilirubinaemia Recent iron infusion
High triglycerides Recent B12 injection
Third trimester of pregnancy† Erythropoietin
Chronic alcohol, opioid and/or high doses of salicylates
Second trimester of pregnancy†
*Especially in African-Caribbean people
†However, changes are small (<1%)
Table 1. Factors that affect HbA1c (adapted from Herman, 2009; Nithin, 2010; WHO, 2011; Larese, 
2012). 
“A number of factors 
can affect HbA1c , 
especially conditions 
that affect red 
blood cell survival 
and non-enzymatic 
glycosylation of 
haemoglobin.”
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correlates with the mean serum glucose. Thus, 
HbA
1c
 specifically refers to glycohaemoglobin 
where glucose binds to the terminal valine of 
the beta-haemoglobin chain to form an adimine 
link, which undergoes an Amadori reaction and 
forms a stable ketoamine link.  
Glycosylated and non-glycosylated hexapeptides 
are separated using HPLC and quantified. HbA
1c
 
is reported as the ratio of its concentration 
to total HbA (Jeppsson et al, 2002) and 
represents the average blood glucose over the 
preceding 2–3 months (Nitin, 2010). Fasting 
plasma glucose (FPG) and post-prandial 
glucose (PPG) have the same effect on HbA
1c
 
<53–64 mmol/mol (7.3–8.4%). However, 
FPG has a greater effect when HbA
1c
 is 
>63 mmol/mol (8.5%); the higher the HbA
1c
, the 
more FPG contributes to total blood glucose.
HbA1c assays
Several assay methods are used to measure 
HbA
1c
 including iron exchange, HPLC, 
chemiluminiscent immunoassays, boronate 
affinity and enzymatic methods (Herman 
2009; Nitin 2010). The US-based National 
Glycohemoglobin Standardisation Program 
was established in 1996 to standardise the 
various methods to the DCCT trial equivalent 
methods (Herman, 2009). Each year the 
College of American Pathologists compares 
within and between HbA
1c
 values and publishes 
the findings. These initiatives have improved 
comparability among the various methods. 
However, as indicated, a number of factors, 
independent of the method, can affect the 
results (Box 1 and Table 1) and need to be 
considered when interpreting the individual’s 
HbA
1c
 results.
Considering the individual
The preceding information raises several 
important points that support the need to 
interpret the HbA
1c
 results in the context of the 
individual, including whether the HbA
1c 
value is 
diagnostic of diabetes, warrants a management 
change, or represents a complication risk. 
HbA
1c
 does not always ref lect the individual’s 
blood glucose self-monitoring pattern for a 
number of reasons, including inaccurate testing 
technique. HbA
1c
 is unreliable when erythrocyte 
abnormalities are present (d’Emden et al, 2012) 
and in the presence of haemoglobinopathies 
(Weber and Schnell, 2009) and anaemia. Weber 
and Schnell (2009) reported that seven out 
of 29 people (24%) with lower than expected 
HbA
1c
 based on their home blood glucose test 
results had a haemoglobinopathy detected on 
electrophoreses.
Haemoglobinopathies are inherited abnormalities 
of haemoglobin and are often asymptomatic. 
Haemoglobinopathies are one of the most 
common factors affecting HbA
1c
 levels 
worldwide, depending on the assay used to 
measure HbA
1c
. Most HbA
1c
 assays assume 
the individual has a normal erythrocyte 
lifespan and that the assay method is specific 
for non-enzymatic adduction of glucose to 
haemoglobin, which may not be the case if the 
individual has a haemoglobinopathy. There 
are several haemoglobinopathies, including 
thalassaemia and many other Hb variants (see 
Box 1). Haemoglobinopathies commonly occur 
in people from Africa, the Mediterranean 
and south-east Asia and are uncommon in 
Caucasian people. Research has shown that the 
difference in HbA
1c
 between Black people and 
Caucasian people becomes greater as the blood 
glucose increases, and is higher in Black people 
than Causcasian people at the same blood 
glucose level (Ziemer et al, 2010).  
Many countries have multicultural 
populations and intermarriage is 
becoming increasingly common; therefore, 
health professionals need to consider 
haemoglobinopathies and other factors that 
affect HbA
1c
 when interpreting results.  It is 
possible to screen for haemoglobinopathies 
but few countries have haemoglobinopathy 
screening programmes in place. The British 
Society for Haematology developed guidelines 
for antenatal and newborn haemoglobinopathy 
screening, which recommend selectively 
screening high-risk women and that universal 
screening might be warranted in areas with a 
high proportion of at-risk individuals (Ryan 
et al, 2010). It is not clear whether these 
recommendations are in routine use.  Screening 
for haemoglobinipathies does not appear to be 
Page points
1. HbA1c is reported as the 
ratio of its concentration to 
total HbA (Jeppsson et al, 
2003) and represents the 
average blood glucose over 
the preceding 2–3 months. 
2. It is important to interpret the 
HbA1c results in the context 
of the individual, including 
whether the HbA1c value is 
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one of the most common 
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worldwide, depending on the 
assay used to measure HbA1c.
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established in other countries.
HbA
1c
 can be spuriously elevated or lowered 
by a number of interfering factors besides 
haemoglobinopathies. For example, factors 
that reduce the lifespan of red blood cells lead 
to low HbA
1c
. Factors that lead to increased 
HbA
1c
 include infections and medicines such 
as corticosteroids and antipsychotics. Table 1 
depicts some factors known to reduce or increase 
HbA
1c
.
Person-centred care is an important 
philosophy underlying modern diabetes 
education and management, and this should be 
applied to interpreting HbA
1c
. HbA
1c
 is part of 
an individual’s clinical picture and needs to be 
considered in context because it does not portray 
the whole picture. 
Factors that affect the HbA
1c 
need to be 
identified and managed. In addition, it is 
important to:
l Involve the individual and any family 
members or carers in decisions about 
investigative procedures and care.
l Listen to the individual with diabetes and ask 
appropriate questions to identify factors that 
could inf luence education and management 
decisions.
l Understand haemoglobinopathies are rare in 
Caucasian people, but do occur, especially 
in multicultural societies. Consider whether 
individuals from at-risk groups should be 
screened for a haemoglobinopathy.
l Realise very few countries have 
effective screening programs to detect 
haemoglobinopathies before or at birth. 
Thus, the true prevalence may be unknown in 
specific countries and populations.
l Consider common and uncommon factors 
that increase or lower HbA
1c
 when deciding an 
individual’s diabetes management regimen.
l Consider using fructosamine to monitor 
glycaemic status as an alternative to HbA
1c
 
in individuals where HbA
1c
 is unreliable. 
Fructosamine assays have been available 
since the 1980s but are not widely used in 
most countries. Fructosamine is formed 
in a non-enzymatic process where protein, 
especially serum albumin, is glycosylated. 
Fructosamine ref lects the average blood 
glucose over the preceding 14–21 days; 
therefore, it can be useful to monitor 
short-term management changes, especially 
during pregnancy. There is no standard 
reference range for fructosamine; generally, 
the higher the fructosamine level, the higher 
the blood glucose. Like other targets, the 
fructosamine target should be individualised 
in collaboration with the individual. Any 
condition that affects serum albumin, such 
as nephritic syndrome or malnutrition, can 
interfere with the fructosamine result. Thus, 
the individual’s health status and context must 
be considered when interpreting fructosamine 
results.
l Know the factors that lower HbA
1c
 could 
impact on its utility as a diagnostic tool and 
that diagnoses could be missed or delayed 
and place the individual at risk of diabetes 
complications.
l Include prompts on pathology reports to 
alert health professionals to the need to 
check the individual’s blood glucose pattern 
and consider the possibility of red blood 
cell abnormalities and other HbA
1c
-related 
interfering factors if the HbA
1c
 is repeatedly 
42 mmol/mol (6%). Alerts are often used 
in this way to signal high HbA
1c
. However, 
clinicians might only refer to the results and 
not consider alert messages in busy clinical 
settings.
Managing diabetes is complicated for both 
health professionals and people with diabetes. It 
is important to individualise care and respect the 
person’s accumulated life and diabetes expertise. 
A number of factors beside blood glucose affect 
HbA
1c
 levels and need to be considered when 
making therapeutic and diagnostic decisions. 
Clearly, HbA
1c
 (and fructosamine, if it is used) 
is only part of the individual’s diabetes story 
and should be considered with blood glucose 
self-monitoring tests and other important 
information.   n
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